Showing 1,261 - 1,280 results of 54,307 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (mean decrease)) ))', query time: 1.52s Refine Results
  1. 1261

    DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  2. 1262
  3. 1263

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  4. 1264

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  5. 1265

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  6. 1266
  7. 1267
  8. 1268

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  9. 1269
  10. 1270
  11. 1271
  12. 1272
  13. 1273

    Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues. by Kumaraswamy Naidu Chitrala (612025)

    Published 2014
    “…<p>Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues.…”
  14. 1274

    Investigating the shared genetics of non-syndromic cleft lip/palate and facial morphology by Laurence J. Howe (5579186)

    Published 2018
    “…Follow-up MR analyses supported a causal relationship; genetic variants for nsCL/P homogeneously cause decreased philtrum width. In addition to the primary analysis, we also identified two novel risk loci for philtrum width at 5q22.2 and 7p15.2 in our Genome-wide Association Study (GWAS) of 6,136 individuals. …”
  15. 1275
  16. 1276
  17. 1277

    Resveratrol Prevents Oxidative Stress-Induced Senescence and Proliferative Dysfunction by Activating the AMPK-FOXO3 Cascade in Cultured Primary Human Keratinocytes by Yasuo Ido (172159)

    Published 2015
    “…In addition, we found that treatment of keratinocytes with Ex527, a specific inhibitor of sirtuin 1 (SIRT1), attenuated the ability of resveratrol to suppress senescence. …”
  18. 1278
  19. 1279
  20. 1280